Business Context and Reporting Period
This Form 8-K, filed on December 28, 2023, reports on events occurring on December 21 and December 26, 2023, involving PowerUp Acquisition Corp. (the "Registrant" or "PowerUp"). The filing details the entry into a definitive merger agreement with Visiox Pharmaceuticals, Inc. ("Visiox"), a Delaware corporation. The transaction involves the merger of a PowerUp subsidiary with Visiox, with Visiox surviving as a wholly-owned subsidiary of PowerUp. PowerUp is an emerging growth company incorporated in the Cayman Islands, which plans to domesticate as a Delaware corporation in connection with the transaction.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, or cash flow statements for the reporting period. Instead, it outlines the financial structure of the proposed merger:
- Merger Consideration: The aggregate value is set at $80,000,000, subject to adjustments for Net Working Capital, transaction expenses, indebtedness, and the value of Rollover RSUs.
- Earnout Provisions: Up to 6,000,000 additional shares of common stock may be issued based on performance milestones:
- Launch Earnout: 2,000,000 shares (1M to stockholders, 1M to Sponsor) if the first commercial sale of Omlonti occurs within 12 months of closing.
- $12.50 Price Target: 2,000,000 shares if the VWAP exceeds $12.50 for 20 of 30 consecutive trading days within 36 months.
- $15.00 Price Target: 2,000,000 shares if the VWAP exceeds $15.00 for 20 of 30 consecutive trading days within 36 months.
- Liquidity Requirement: A closing condition requires PowerUp to have at least $5,000,000 in cash available (from the Trust Account or a concurrent PIPE) after redemptions and expenses.
- Debt and Financing:
- PowerUp entered a Loan and Transfer Agreement on December 21, 2023, involving a $250,000 loan to the Sponsor (8% interest) and a $250,000 non-interest-bearing loan from the Sponsor to PowerUp.
- Visiox's outstanding convertible promissory notes will be assumed by PowerUp.
Material Changes and Transaction Structure
The primary material change is the execution of the Merger Agreement, which fundamentally alters the Registrant's business from a blank-check company to a combined entity focused on Visiox's pharmaceutical assets. Key structural changes include:
- Domestication: PowerUp will migrate from the Cayman Islands to Delaware.
- Capital Structure Conversion: All existing PowerUp securities (Units, Class A/B shares, Warrants) will convert on a one-for-one basis into new Delaware corporation securities immediately prior to the merger.
- Board Composition: The post-closing board will consist of five directors: two designated by PowerUp (both independent) and three by Visiox (at least one independent).
- Management: The CEO and CFO of Visiox will become the CEO and CFO of the combined company.
Guidance, Risks, and Contingencies
The filing contains extensive forward-looking statements regarding the anticipated benefits and timing of the transaction, which are subject to significant risks.
- Closing Conditions: The transaction is contingent upon shareholder approval from both PowerUp and Visiox, SEC effectiveness of the registration statement (Form S-4), Nasdaq listing approval, and the satisfaction of the $5,000,001 minimum net tangible asset test.
- Termination Rights: The agreement may be terminated by either party if closing conditions are not met by the "Outside Date" of May 31, 2024, or in the event of a Material Adverse Effect, regulatory prohibition, or failure to obtain shareholder approval. No termination fees are provided.
- Key Risks:
- Failure to complete the transaction by the business combination deadline.
- Redemptions by PowerUp shareholders exceeding anticipated levels, potentially jeopardizing the minimum cash requirement.
- Regulatory and clinical risks associated with Visiox's product candidates, specifically Omlonti.
- Disruption of Visiox's business operations during the pendency of the transaction.
Investor Verification Checklist
- Verify the status of the Form S-4 registration statement and the upcoming shareholder vote dates for both PowerUp and Visiox.
- Monitor the Trust Account balance and redemption levels to ensure the $5,000,000 minimum cash condition can be met at closing.
- Review the Merger Agreement (Exhibit 2.1) for specific details on the treatment of Visiox's convertible notes and preferred stock.
- Assess the clinical and commercial timeline for Omlonti to evaluate the likelihood of achieving the "Launch Earnout" milestone.
- Confirm the domestication process from Cayman Islands to Delaware and the resulting tax implications for shareholders.